Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Items 901–937 of 937
Preclinical evaluation of senescence-based strategies to improve cancer therapy
Estepa‐Fernández, A. (2022) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/188845
CDk Inhibitor for Treatment of Breast Cancer
Mir, M. A., Gul, A., Sofi, S., & Khan, M. S. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_15 · Cited by 1
Ray, D., Terao, Y., Nimbalkar, D., Hirai, H., Osmundson, E. C., Zou, X., Franks, R. R., Christov, K. T., & Kiyokawa, H. (2023) · doi:10.1158/0008-5472.c.6495773
Kobayashi, S. S., Shimamura, T., Monti, S., Steidl, U. G., Hetherington, C. J., Lowell, A. M., Golub, T. R., Meyerson, M. M., Tenen, D. G., Shapiro, G. I., et al. (2023) · doi:10.1158/0008-5472.c.6495248
Kobayashi, S. S., Shimamura, T., Monti, S., Steidl, U. G., Hetherington, C. J., Lowell, A. M., Golub, T. R., Meyerson, M. M., Tenen, D. G., Shapiro, G. I., et al. (2023) · doi:10.1158/0008-5472.c.6495248.v1
Kilker, R. L., & Planas-Silva, M. D. (2023) · doi:10.1158/0008-5472.c.6494916.v1
Kilker, R. L., & Planas-Silva, M. D. (2023) · doi:10.1158/0008-5472.c.6494916
Data from Role of Cyclin D1 as a Mediator of c-Met– and β-Catenin–Induced Hepatocarcinogenesis
Patil, M. A., Lee, S. A., Macias, E., Lam, E. T., Xu, C., Jones, K. D., Ho, C., Rodríguez‐Puebla, M. L., & Chen, X. (2023) · doi:10.1158/0008-5472.c.6498158
Data from Role of Cyclin D1 as a Mediator of c-Met– and β-Catenin–Induced Hepatocarcinogenesis
Patil, M. A., Lee, S. A., Macias, E., Lam, E. T., Xu, C., Jones, K. D., Ho, C., Rodríguez‐Puebla, M. L., & Chen, X. (2023) · doi:10.1158/0008-5472.c.6498158.v1
Fereshteh, M., Tilli, M. T., Kim, S. E., Xu, J., O’Malley, B. W., Wellstein, A., Furth, P. A., & Riegel, A. T. (2023) · doi:10.1158/0008-5472.22370952
Investigating post-translational modification of cyclin D1 in breast cancer
Radel, S. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.240785
Melo, L. D. P. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-04082023-145119
Multistage Carcinogenesis: Cell and Animal Models
Kulesz-Martin, M. F., Ouyang, X., Ramin, S., Barling, A. N., Gallegos, J. R., Liu, Y., & Medler, T. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00085-1
Tomblyn, S. (2007) · TigerPrints (Clemson University)
Anchorage-independent nuclear localization of cyclin D1 in v-Ki-ras-expressing NIH3T3 cells
森, 一., 外谷, 陽., 野瀬, 清., & 柴沼, 質. (2008) · doi:10.11418/jtca.27.125
The Role of E2F Transcription Factors in Oncogene Mediated Mammary Tumorigenesis
House, M. (2007) · The Knowledge Bank (The Ohio State University)
Chiche, A. (2012) · theses.fr (ABES) · doi:10.70675/67609440zb6dez49d8z872az1256bad88650
“Ainsi, afin de déterminer si Myc est nécessaire à la formation de ces tumeurs, nous avons croisé les souris K5ΔNβcat avec les RÉSULTATS : L’activation de la voie Wnt/β-caténine induit une amplification des progéniteurs basaux et des tumeurs de type basal dépendante de l’activation de Myc 124 souris K5Cre; MycF/F dont…”
MethodInfluentialLadam, F. (2010) · theses.fr (ABES) · doi:10.70675/e175f6dbz92dez451cza5a0z5ba11dc8c915
Étude de la fonction transcriptionnelle de la parkine dans les cancers cérébraux
Rouland, L. (2019) · theses.fr (ABES) · doi:10.70675/144669dcz5f62z47dcz9bd6z551bd742d8f9
Kutsebko, D. N., & Glushakov, R. I. (2026) · Malignant tumours · doi:10.18027/2224-5057-2026-067
Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
Dernovšek, J., Cingl, J., Fonović, U. P., & Tomašič, T. (2026) · Medicinal Research Reviews · doi:10.1002/med.70079
Liu, Y., Parris, A. B., Ma, Z., Wei, L., Qi, Y., & Yang, X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.14.751306
Feng, X., Li, N., Chen, X., Cao, X., Dai, J., Xiong, S., & Yuan, Z. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118532
BindingDB (2011) · UC San Diego · doi:10.7270/q2t72hqv
BindingDB Entry 50043232: Pin1 inhibitors: Pitfalls, progress and cellular pharmacology.
BindingDB (2014) · UC San Diego · doi:10.7270/q2dv1m9t
BindingDB Entry 50006245: Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
BindingDB (2020) · UC San Diego · doi:10.7270/q21v5hz6
Functional redundancy between atypical CDKs reveals a vulnerability in hepatocellular carcinoma
Martínez‐Alonso, D., Nogueira, E., López-Sainz, L. R., Pérez, A. P., Villarroya‐Beltri, C., Garcia-Diaz, A., Bonel-Pérez, G. C., Bakkali, A. E., Wakahashi, S., Sánchez-Belmonte, A., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2529474123
Jacquemart, I. (2006) · TigerPrints (Clemson University)
The role of prolactin and its antagonist in HER2/neu tumorigenesis
Scotti, M. L. (2006) · TigerPrints (Clemson University)
Knights, C. D., & Pestell, R. G. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-337-0_1
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.